DiaMedica Therapeutics Inc. DMAC
10.77 USD +0.77 (+7.70%)
At closeNov 4, 2026, 4:01 PM EST
10.77 0.00 0.00%
After hours · Nov 4, 4:01 PM ET
10.15 Day range 11.00
5.25 52-week range 11.00
- YTD
- +35.30%
- 1 year
- +60.51%
News
gurufocus.com DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth res
benzinga.com DiaMedica Therapeutics Enrolls 200th Patient In ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-EstimationInterim Analysis Results Expected in Q1 2027
businesswire.com DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
businesswire.com DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
businesswire.com DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
gurufocus.com DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth res
businesswire.com DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
zacks.com Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 130% in DiaMedica Therapeutics (DMAC). While the effectiveness of this highly sought-after metric is…
zacks.com All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy DiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
seekingalpha.com DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
benzinga.com HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.
marketbeat.com DiaMedica Therapeutics Q2 Earnings Call Highlights DiaMedica Therapeutics NASDAQ: DMAC said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the…
benzinga.com DiaMedica Therapeutics Q2 EPS $(0.19) Beats $(0.20) Estimate DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 5.56 percent decrease over losses of…
businesswire.com DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
businesswire.com DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
businesswire.com DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
benzinga.com Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrollment of first patient in phase 3 trial.
gurufocus.com DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction a
benzinga.com DiaMedica Therapeutics Doses First Patients In Its Phase 2 Trial Of DM199 For The Treatment Of Fetal Growth Restriction First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatmentDM199 is intended to improve maternal…
businesswire.com DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute…
benzinga.com DiaMedica Receives FDA Written Response About The Need For Additional Nonclinical Reproductive Toxicity Data To Support Continued Development Of DM199 For The Treatment Of Preeclampsia DiaMedica believes, based on the FDA's feedback, that the previously completed rat reproductive toxicity study may be acceptable to support a U.S. investigational new drug (IND) application, provided…
businesswire.com DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and…
businesswire.com DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…- benzinga.com DiaMedica Therapeutics Announces 75% Enrollment In Its Phase 2/3 ReMEDy2 trial of DM199 In Patients With Acute Ischemic Stroke ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpasses 75% of Enrollment Required to Trigger Pre-Specified Interim AnalysisInterim Analysis by Independent DSMB Expected to Determine if a Sample Size…
businesswire.com DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and…
businesswire.com DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction…
seekingalpha.com DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com DiaMedica Therapeutics Q1 EPS $(0.19), Inline DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a 5.56 percent decrease over losses of $(0.18) per share from the…
- benzinga.com Earnings Scheduled For March 30, 2026
benzinga.com Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.- benzinga.com DiaMedica Therapeutics Gets No Objection Letter From Health Canada For Its Clinical Study Application Of DM199 In Phase 2 Trial In Participants With Early-Onset Preeclampsia DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke…
benzinga.com DiaMedica Therapeutics Completes Productive In-Person Pre-IND Meeting With FDA For Planned Study Evaluating DM199 In Preeclampsia DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com Cantor Fitzgerald Initiates Coverage On DiaMedica Therapeutics with Overweight Rating, Announces Price Target of $25 Cantor Fitzgerald analyst Josh Schimmer initiates coverage on DiaMedica Therapeutics (NASDAQ:DMAC) with a Overweight rating and announces Price Target of $25.
- benzinga.com DiaMedica Therapeutics Q3 EPS $(0.17), Inline DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.17) per share which met the analyst consensus estimate. This is a 13.33 percent decrease over losses of $(0.15) per share from…
- benzinga.com Earnings Scheduled For November 12, 2025
benzinga.com An Overview of DiaMedica Therapeutics's Earnings 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.
benzinga.com DiaMedica Therapeutics Q2 EPS $(0.18) Beats $(0.19) Estimate DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 38.46 percent decrease over losses…- benzinga.com Earnings Scheduled For August 12, 2025
- benzinga.com Exploring DiaMedica Therapeutics's Earnings Expectations
- benzinga.com Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $11 Craig-Hallum analyst Chase Knickerbocker maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $8 to $11.
- benzinga.com Lake Street Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $14 Lake Street analyst Thomas Flaten maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $11 to $14.
- benzinga.com HC Wainwright & Co. Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $12 HC Wainwright & Co. analyst Matthew Caufield maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $10 to $12.
- benzinga.com DiaMedica Therapeutics Announces Interim Results From Part 1a Of Phase 2 Study Of DM199 For Treatment Of Preeclampsia Conference Call Today July 17, 2025 at 4:30 PM Eastern Time / 3:30 PM Central TimeDM199 Demonstrated Highly Statistically Significant and Clinically Meaningful Reductions in Systolic and Diastolic…
benzinga.com HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $10 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $10 price target.